Plaque Rupture and Thrombosis
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“Plaque rupture with thrombosis drives ACS, and thin-cap fibroatheroma is the archetypal high-risk plaque. There are consistent features of vulnerability across imaging modalities (large plaque burden, small MLA, TCFA, high LCBI, positive remodelling, etc.), with risk increasing when multiple features coexist. Yet absolute event rates remain low, consistent with pathology data showing most plaque ruptures are clinically silent.
So should we prophylactically stent high-risk plaques? According to this Viewpoint, completed trials (PROSPECT ABSORB, PREVENT) suggest no durable reduction in death or MI versus optimal medical therapy—benefits are limited to fewer revascularisations, at the cost of many unnecessary PCIs. With modern medical therapy, a wait-and-see strategy appears safe, avoiding most interventions without adverse consequences. For now, data favor surveillance and aggressive medical therapy over preventive PCI.
READ THE VIEWPOINT HERE.
Stay updated with Hemostasis Today.
-
Nov 2, 2026, 02:56Leonhard Stärk: The Future of Universal Donor-Free Red Blood Cells
-
Nov 2, 2026, 02:45Marija Tashkovska: Advancing Transfusion Medicine Through Collaboration
-
Nov 2, 2026, 02:32Rachel Rosovsky: Pulmonary Embolism During Pregnancy and Postpartum
-
Nov 2, 2026, 02:26Jaromir Vajter: Bleeding Risks and Anticoagulation After ECPR
-
Nov 2, 2026, 02:13Maia Meier: 111 Kilometres on Skis to the South Pole
-
Nov 1, 2026, 23:49Austin Reese: Should Anticoagulation for AF Continue When Patients Move into Long-Term Care?
-
Nov 1, 2026, 23:43Abdelmonam Hagag: Mechanical Thrombectomy vs Anticoagulation in Acute Pulmonary Embolism New Meta Analysis
-
Nov 1, 2026, 23:38Ankur Garg: Safe Water and Nutrition as Economic Investments for LMIC Demographic Dividends
-
Nov 1, 2026, 23:30Ana Paula Tagliari: FIH Experience with Penumbra Lightning Flash 2.0 at TCT 2026